Navigation Links
New results validating Pall prion reduction filter disclosed at ISBT Congress

detect vCJD. Although tests are in development by several companies, no solutions are likely in the short-term. He reviewed the complexity of developing accurate and reliable tests that would meet the required criteria including sensitivity and specificity. The implementation of donor screening would be problematic without the availability of confirmatory assays to inform discussions with potentially infected donors.

Prion Reduction Confirmed

Sam Coker, Ph.D., Principal Scientist of Pall Corporation, released new research results that further support the performance of the Leukotrap Affinity Prion Reduction Filter System. The study, conducted with the Departments of Neurology, Psychiatry and Pathology of the New York University School of Medicine, tested the filter against sporadic CJD. Sporadic CJD is the most common form of prion disease that affects humans. The new research showed a 99.9 percent reduction of the prion.

"This study, a first with an actual human form of prion disease, provides additional confirmation of the performance of our technology to remove all types of prions that can adversely affect people," said Dr. Coker. The sporadic CJD study is the latest in a series of studies of the filter's capability in reducing prions, including scrapie (a prion disease affecting sheep) and mouse-adapted human vCJD. He also reviewed results of new studies that found the filter effectively reduced prions under a range of different blood processing conditions, which may vary by country and blood center.

Allan Ross, President of Pall Medical, who opened the symposium, noted that concerns about vCJD are not limited to the UK and Europe, but that the disease has manifested itself in many countries around the globe. A total of 177 people have died or been diagnosed with vCJD in Britain, Ireland, France, Canada, Italy, Portugal, the Netherlands, Japan and the U.S. This past month France identified its 13th person with vCJD and Portugal a
'"/>

Source:Pall Corporation


Page: 1 2 3

Related biology news :

1. Gene vaccine for Alzheimers disease shows promising results
2. Roche clinical trial registry and results database launched
3. Diabetic nerve therapy shows striking results
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
6. Combination therapy shows promising results in patients with advanced lung cancer
7. Vaccine for brain tumors shows promising results
8. Artificial cornea offers better results for infants, some blind patients
9. Encouraging results in pancreatic cancer research
10. The eyes have it -- Autism research yields surprising results
11. UCSF brain tumor vaccine trial shows promising results
Post Your Comments:
(Date:7/30/2014)... (ACS) announced today that David L. Kaplan, Ph.D., will ... & Engineering as editor-in-chief. With the first issue ... will feature high-quality research in the rapidly burgeoning field ... materials that interact with living or biological systems. , ... tremendous growth in the field of biomaterials over the ...
(Date:7/30/2014)... knows the shortest distance between two points is a ... sperm have been taking the familiar axiom to heart. ... thought to be intense, with each racing for the ... some species, sperm form cooperative groups that allow them ... , A new study, conducted by Heidi Fisher, a ...
(Date:7/30/2014)... the University of Helsinki and the Universitat Autnoma de ... morphological changes which have taken millions of years to ... development of mice teeth, induced in the laboratory, scientists ... those observed in the fossil registry of rodent species ... , To modify the development of their teeth, the ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2When cooperation counts 2When cooperation counts 3Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... It,s long been known that alcohol use in ... birth defects, but researchers who study fetal alcohol syndrome ... disorder, detecting it early, or effectively treating it, say ... the issue of Developmental Neuroscience , four first-year ...
... How do we begin to understand what early life was ... planet shifted from an oxygen-free and probably ice-covered realm to ... who decodes the early record of life on Earth has ... a significantly clearer picture of this dynamic environment. Alison Olcott ...
... , THE WOODLANDS, Texas , June 15 ... company focused on discovering breakthrough treatments for human disease, announced today ... clinical trial of LX4211 for patients with type 2 ... June 19 – 22, 2010 in San Diego, ...
Cached Biology News:Little is understood about alcohol's effect on fetal development, Georgetown researchers say 2Little is understood about alcohol's effect on fetal development, Georgetown researchers say 3Delineating primary and secondary organic carbon in neoproterozoic glacial sediments 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 3Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 4Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 5
(Date:7/31/2014)... July 31, 2014 SoundConnect ... collaboration company, is proud to announce the addition ... complements Adobe Connect’s elearning tools to quickly deploy ... content with training tools for desktop and mobile ... LMS is the perfect online training solution, enabling ...
(Date:7/30/2014)... 2014 Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended June 30, 2014 on Wednesday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its second quarter ...
(Date:7/30/2014)... , July 30, 2014 A ... evaluated the safety and efficacy of CSL Behring,s ... following kidney transplants in highly sensitized patients. C1-INH ... of the complement system. The study ... significant increases in the levels of complement components ...
(Date:7/30/2014)... Selexis SA , a serial innovation ... mammalian cell line development, announced today new data from ... presented at the 10th Annual Cell Line Development ... 10, 2014 at the Double Tree by Hilton Berkeley ... will be presented during an oral presentation: , Title: ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... LEUVEN, Belgium and LUND, Sweden, September 7 ... Anticoagulant Into Phase,II Clinical Development ThromboGenics NV ... disease, and co-development partner, BioInvent,International (Nordic Exchange: BINV), ... initial follow-up of all volunteers,in the first Phase ...
... 6 Globally, approximately 418 billion,people are currently ... costs of hepatitis in the 21st century cannot ... a,new report by Kalorama Information. Paradoxically, despite ... necessary steps to contain hepatitis. Yet the incidence ...
... VRUS ) and Roche (OTC: RHHBY) announced ... the treatment of chronic hepatitis C,virus (HCV) will ... Hepatitis C,Virus and Related Viruses being held from ... of PSI-6130, is an oral cytidine nucleoside,analog polymerase ...
Cached Biology Technology:ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 5Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
... Experion HighSens analysis kit for 25 chips ... perform high-sensitivity RNA analysis (at picogram levels) ... kit includes 25 RNA HighSens microfluidic chips, ... x 20 microliters RNA HighSens stain, 20 ...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... The Experion StdSens analysis kit for ... required to perform standard-sensitivity RNA analysis (at ... system. This kit includes 25 RNA StdSens ... gel, 2 x 20 microliters RNA StdSens ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White ... GAS. A brain-permeable and water soluble pyrimidinone ... NAD + -competitive inhibitor of PARP (IC ... nM for rhPARP1 and rmPARP2, respectively) with ...
Biology Products: